Welcome : Guest

Industry : Pharmaceuticals


103 Record(s).
CODE TITLE DOP
MCP-6917 Fibromyalgia Therapeutics - A Global Strategic Business Report 04/2017
MCP-6845 Acute Heart Failure (AHF) Therapeutics - A Global Strategic Business Report 03/2017
MCP-6847 Acute Myeloid Leukemia (AML) Therapeutics - A Global Strategic Business Report 03/2017
MCP-7937 Radiation Detection, Monitoring and Safety - A Global Strategic Business Report 02/2017
MCP-6233 Cystic Fibrosis - A Global Strategic Business Report 02/2017
MCP-6195 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - A Global Strategic Business Report 01/2017
MCP-1241 Regenerative Medicine - A Global Strategic Business Report 01/2017
MCP-7129 Human Growth Hormone Drugs - A Global Strategic Business Report 01/2017
MCP-7500 Pulmonary Arterial Hypertension (PAH) Therapeutics - A Global Strategic Business Report 01/2017
MCP-6815 Peripheral Arterial Disease (PAD) Therapeutics - A Global Strategic Business Report 01/2017
MCP-6525 Sepsis Therapeutics - A Global Strategic Business Report 11/2016
MCP-6433 Endometriosis - A Global Strategic Business Report 10/2016
MCP-1098 Chiral Technology - A Global Strategic Business Report 10/2016
MCP-1176 Prophylactic Human Vaccines - A Global Strategic Business Report 07/2016
MCP-6201 Biosimilars - A Global Strategic Business Report 07/2016
MCP-1129 Veterinary Vaccines - A Global Strategic Business Report 05/2016
MCP-1747 Prostate Cancer Therapeutics - A Global Strategic Business Report 05/2016
MCP-6453 Hormone Replacement Therapy (HRT) - A Global Strategic Business Report 05/2016
MCP-6466 DPP IV Inhibitors - A Global Strategic Business Report 04/2016
MCP-6975 Animal Medication - A Global Strategic Business Report 04/2016
MCP-7743 Artificial Tears - A Global Strategic Business Report 01/2016
MCP-6441 Food Allergy and Intolerance Products - A Global Strategic Business Report 01/2016
MCP-1122 Weight Control Products - A Global Strategic Business Report 01/2016
MCP-1205 Anticoagulants - A Global Strategic Business Report 01/2016
MCP-7916 Human Reproductive Technologies - A Global Strategic Business Report 11/2015
MCP-7003 Biopharmaceuticals - A Global Strategic Business Report 05/2015
MCP-6940 Ion Channel Modulators - A Global Strategic Business Report 04/2015
MCP-7443 Orphan Drugs - A Global Strategic Business Report 04/2015
MCP-6274 H1N1 Vaccines - A Global Strategic Business Report 03/2015
MCP-6280 Huntingtons Disease Therapeutics - A Global Strategic Business Report 03/2015
MCP-1835 CNS Therapeutics - A Global Strategic Business Report 02/2015
MCP-2542 Vitamins - A Global Strategic Business Report 01/2015
MCP-7776 Intravenous Immunoglobulin (IVIg) - A Global Strategic Business Report 01/2015
MCP-6464 Intravenous (IV) Iron Drugs - A Global Strategic Business Report 01/2015
MCP-6770 Testosterone Replacement Therapy (TRT) - A Global Strategic Business Report 01/2015
MCP-6503 Pediatric Drugs and Vaccines - A Global Strategic Business Report 09/2014
MCP-1722 Anti-Obesity Drugs - A Global Strategic Business Report 05/2014
MCP-7877 Personalized Medicines - A Global Strategic Business Report 03/2014
MCP-6797 Kidney Cancer Drugs - A Global Strategic Business Report 05/2012
MCP-1092 Angiongenesis Inhibitors and Stimulators - A Global Strategic Business Report 05/2012
MCP-1130 Pain Management - A Global Strategic Business Report 05/2012
MCP-1229 Osteoporosis Therapeutics - A Global Strategic Business Report 05/2012
MCP-6052 Immunochemicals - A Global Strategic Business Report 04/2012
MCP-6392 Anxiety Disorders - A Global Strategic Business Report 04/2012
MCP-6819 RNA Interference (RNAi) - A Global Strategic Business Report 04/2012
MCP-6451 Herpes Simplex Virus Treatment - A Global Strategic Business Report 04/2012
MCP-1551 Cancer Therapies - A Global Strategic Business Report 10/2011
MCP-1857 Multiple Myeloma Therapeutics - A Global Strategic Business Report 10/2011
MCP-1829 Autoimmune Disease Therapeutics - A Global Strategic Business Report 10/2011
MCP-6499 Overactive Bladder (OAB) Therapeutics - A Global Strategic Business Report 08/2011
MCP-6829 ePharmacies - A Global Strategic Business Report 08/2011
MCP-6714 Bone and Joint Health Supplements - A Global Strategic Business Report 08/2011
MCP-6796 Irritable Bowel Syndrome (IBS) Therapeutics - A Global Strategic Business Report 08/2011
MCP-1705 Antibiotics - A Global Strategic Business Report 10/2010
MCP-1490 Opthalmic Pharmaceutical Drugs - A Global Strategic Business Report 10/2010
MCP-5064 Analgesics - A Global Strategic Business Report 10/2010
MCP-6020 Bladder Cancer Therapeutics - A Global Strategic Business Report 10/2010
MCP-6368 Sleeping Pills - A Global Strategic Business Report 08/2010
MCP-6377 Protein Drugs - A Global Strategic Business Report 08/2010
MCP-6540 Tinea Pedis (Athletes Foot) - A Global Strategic Business Report 08/2010
MCP-6217 Anti-CD20 Monoclonal Antibodies - A Global Strategic Business Report 07/2010
MCP-6202 Bipolar Disorder - A Global Strategic Business Report 06/2010
MCP-6237 Diabetic Retinopathy - A Global Strategic Business Report 06/2010
MCP-6245 Dyslipidemia Therapeutics - A Global Strategic Business Report 04/2010
MCP-6282 Inflammatory Bowel Disease (IBD) Therapeutics - A Global Strategic Business Report 04/2010
MCP-6297 Liver Cancer Drugs - A Global Strategic Business Report 04/2010
MCP-6298 Lymphoma Therapeutics - A Global Strategic Business Report 04/2010
MCP-6303 Melanoma Therapeutics - A Global Strategic Business Report 04/2010
MCP-6311 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 04/2010
MCP-6313 Neurodegenerative Drugs - A Global Strategic Business Report 04/2010
MCP-6317 Pancreatic Cancer Drugs - A Global Strategic Business Report 04/2010
MCP-6324 Psoriasis Drugs - A Global Strategic Business Report 04/2010
MCP-6337 Tuberculosis Therapeutics - A Global Strategic Business Report 04/2010
MCP-6355 Acute Coronary Syndrome - A Global Strategic Business Report 04/2010
MCP-6161 Erectile Dysfunction Drugs - A Global Strategic Business Report 04/2010
MCP-6168 Antibacterial Drugs - A Global Strategic Business Report 04/2010
MCP-6176 HIV Drugs - A Global Strategic Business Report 04/2010
MCP-6192 Anemia Drugs - A Global Strategic Business Report 04/2010
MCP-6016 Lou Gehrigs Disease - A Global Strategic Business Report 04/2010
MCP-1698 Cardiovascular Drugs - A Global Strategic Business Report 04/2010
MCP-1498 Rheumatoid Arthritis Therapeutics - A Global Strategic Business Report 02/2010
MCP-6021 Anti-Hypertensive Drugs - A Global Strategic Business Report 02/2010
MCP-6126 Anti-Migraine Drugs - A Global Strategic Business Report 02/2010
MCP-6151 Cold, Cough, And Sore Throat Remedies - A Global Strategic Business Report 02/2010
MCP-6156 Anti-Infectives - A Global Strategic Business Report 02/2010
MCP-6165 Allergy Drugs - A Global Strategic Business Report 02/2010
MCP-6220 Chronic Obstructive Pulmonary Disease - A Global Strategic Business Report 02/2010
MCP-6268 Glaucoma Pharmaceuticals - A Global Strategic Business Report 02/2010
MCP-1873 Lung Cancer Therapeutics - A Global Strategic Business Report 07/2009
MCP-1779 Prescription Drugs - A Global Strategic Business Report 07/2009
MCP-1723 Small Molecule Kinase Inhibitors - A Global Strategic Business Report 07/2009
MCP-1858 Hepatitis C Virus And Therapeutics - A Global Strategic Business Report 04/2009
MCP-1208 Bulk Paclitaxel - A Global Strategic Business Report 10/2008
MCP-1704 Alzheimers And Parkinsons Diseases - A Global Strategic Business Report 05/2008
MCP-1591 Smoking Cessation Aids - A Global Strategic Business Report 04/2008
MCP-1689 Colorectal Cancer Therapeutics - A Global Strategic Business Report 10/2006
MCP-1761 Antivirals - A Global Strategic Business Report 10/2006
MCP-1553 Breast Cancer Therapeutics - A Global Strategic Business Report 10/2006
MCP-1566 Asthma Therapeutics - A Global Strategic Business Report 10/2006
MCP-1222 Lipid Regulators - A Global Strategic Business Report 08/2006
MCP-1577 Respiratory Drugs - A Global Strategic Business Report 07/2006
MCP-1230 Ovarian Cancer Therapeutics - A Global Strategic Business Report 02/2006
MCP-1383 Antidepressants - A Global Strategic Business Report 02/2006